UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of ~~March~~April 2026

Commission File Number: 001-41661

Jin Medical International Ltd.

(Exact name of registrant as specified in its charter)

No. 33 Lingxiang Road, Wujin District

Changzhou City, Jiangsu Province

People’s Republic of China

(Address of Principal Executive Office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

~~1-for-20~~Nasdaq ~~Share~~Minimum ~~Combination~~Bid Price Requirement Compliance Regained and Press Release

AsOn ~~previously~~April ~~disclosed in the report on Form 6-K filed with the U.S. Securities and Exchange Commission (the “SEC”) on February 4~~2, 2026 by , Jin Medical International Limited, an exempted company incorporated in the Cayman Islands (the “Company”), atreceived ~~the~~written ~~Company’s~~notice ~~extraordinary general~~from ~~meeting~~the ~~held~~Nasdaq Listing onQualifications ~~January~~Department ~~30, 2026~~ (the “~~EGM~~Staff”), ~~the~~of ~~Company’s~~The ~~shareholders~~Nasdaq ~~approved~~Stock upMarket toLLC ~~three~~(“Nasdaq”) ~~share~~that ~~consolidations of~~ the Company’s ~~authorized~~had ~~and~~regained ~~issued~~compliance ~~ordinary~~with ~~shares~~Listing ~~within~~Rule ~~two~~5550(a)(2) ~~years from~~ (the ~~date~~“Minimum ofBid ~~the~~Price ~~EGM~~Requirement”). atThe ~~the pre-determined consolidation ratios approved at the EGM, to be effected if the~~ closing ~~market~~ bid price of the Company’s Class A ordinary shares ishad ~~less~~been ~~than~~at US$1.00~~. The~~ ~~Company’s~~per ~~board~~share ofor ~~directors~~greater ~~(the~~for ~~“Board”~~more than ten (10) ~~was~~consecutive ~~authorized~~business days. In particular, inthe ~~its~~Staff ~~sole~~determined ~~discretion,~~that tofor ~~determine~~the ~~whether~~thirteen ~~and when~~(13) toconsecutive ~~effect~~business ~~any~~days ~~such~~from ~~share~~March ~~consolidation~~16, ~~and~~2026 to ~~implement~~April ~~any~~1, ~~such~~2026, ~~consolidation~~the Company inwas ~~accordance~~able ~~with~~to ~~the~~maintain ~~shareholders’~~a ~~approval~~minimum bid price of $1. 00 per share.

OnAs ~~February~~previously 3,disclosed ~~2026~~in the report on Form 6-K filed with the U.S. Securities and Exchange Commission (the “SEC”) on May 2, 2025 by the ~~Board~~Company, ~~approved~~the Company received a ~~combination~~ deficiency letter from the Staff of ~~all~~ Nasdaq informing the Company that, based upon the closing bid price of the Company’s ~~authorized~~ordinary shares ~~and~~over ~~issued~~the ~~Class~~30 Aconsecutive ~~ordinary~~business ~~shares~~day period between March 20, 2025 and ~~Class~~May B1, ~~ordinary~~2025, ~~shares~~the atCompany awas ~~ratio~~not ofin ~~one-for-twenty~~compliance ~~(1-for-20) (~~with the Minimum ~~“Share~~Bid ~~Consolidation”)~~Price Requirement.

InAs ~~addition, as~~ previously disclosed in the ~~report~~Company’s annual report for the fiscal year ended September 30, 2025 on Form 620-KF filed ~~by the Company~~ with the SEC on February 410, 2026, the Company ~~has~~was ~~reclassified its share capital from a single class~~initially ofgranted ~~ordinary shares to~~ a ~~dual~~180-day ~~class~~compliance ofperiod ~~Class~~through AOctober ~~ordinary~~29, ~~shares~~2025, and ~~Class B ordinary shares~~, ~~effective~~after asnot ofregaining ~~the~~compliance ~~date~~during ofthat ~~the~~period, ~~EGM~~Nasdaq ~~(the~~granted ~~“Reclassification”). As a result of~~ the ~~Reclassification and the Share Consolidation, the~~ Company’s ~~authorized~~an ~~share~~additional ~~capital~~180-day ~~became~~compliance ~~US$50,000~~period ~~divided into~~that ~~45,000,000~~commenced ~~Class~~on AOctober ~~ordinary shares of a par value of US$0.001 each~~31, ~~and 5,000,000 Class B ordinary shares of a par value of US$0~~2025.~~001 each.~~

~~The~~As ~~Reclassification~~previously ~~and~~disclosed in the ~~Share~~report ~~Consolidation~~on Form ~~became~~6-K ~~effective~~filed with ~~The~~the ~~Nasdaq~~SEC ~~Stock~~on ~~Market~~March ~~LLC~~17, 2026, the Company’s board of directors (the “~~Nasdaq~~Board”) was authorized pursuant to shareholders’ vote at the Company’s 2026 extraordinary general meeting on January 30, 2026, to determine, in its sole discretion, whether and when to effect any share consolidation in accordance with the shareholders’ approval. On February 3, 2026, the Board approved a combination of all of the Company’s authorized and issued Class A ordinary shares and Class B ordinary shares at a ratio of one-for-twenty (1-for-20) (the “Share Consolidation”). The Share Consolidation became effective with Nasdaq on March 16, 2026 at 09:00 a.m., Eastern Time ~~(the “Effective Time”)~~.

AtAfter the ~~Effective~~Share ~~Time~~Consolidation, ~~every twenty (20) shares of~~ the Company’s authorized ~~and~~share ~~issued~~capital ~~ordinary~~became ~~shares~~US$50,000 ~~(including~~divided ~~all~~into 45,000,000 Class A ordinary shares ~~and~~of ~~Class~~a Bpar ~~ordinary~~value ~~shares)~~of ~~were combined~~US$0.001 ~~into~~each, ~~one~~and ~~(1)~~5,000,000 Class ~~share~~B of ordinary ~~share~~shares inof ~~the~~a ~~respective~~par ~~share~~value ~~class~~of US$0.001 ~~The~~each. ~~number~~As of ~~issued~~the ~~and~~date ~~outstanding shares~~ of ~~Class~~this Acurrent ~~ordinary shares~~report ~~was~~on ~~therefore~~Form ~~reduced~~6-K ~~from~~(this ~~136~~“Report”),~~547,100~~ the ~~shares~~Company tohas 6,827,355 ~~shares,~~Class ~~and~~A ~~the~~ordinary ~~number~~shares of issued and outstanding, ~~shares~~and of1,000,000 Class B ordinary ~~shares~~ ~~was therefore reduced from 20,000,000~~ shares toissued ~~1,000,000~~and ~~shares~~outstanding.

~~The~~On ~~Company~~April ~~believes~~7, 2026, the ~~Share~~Company ~~Consolidation~~published is a ~~proactive~~press release ~~measure~~entitled as“Jin ~~part~~Medical ofInternational ~~the~~Ltd. ~~Company’s~~Has ~~strategic~~Regained ~~plan~~Compliance ~~to maintain compliance~~ with ~~continued~~Nasdaq’s ~~listing~~Minimum ~~requirements~~Bid ofPrice ~~Nasdaq~~Requirement”, ~~while~~a itcopy isof ~~also~~which ~~intended~~is ~~for~~attached ~~strengthening~~hereto ~~the~~as ~~Company’s~~Exhibit ~~long-term capital structure~~99. 1.

~~The~~This ~~Company’s~~Report ~~Class~~shall Abe ~~ordinary~~deemed ~~shares~~to ~~will~~be incorporated ~~continue~~by toreference ~~trade~~into the registration statement on ~~Nasdaq~~Form F-3 ~~under~~(File ~~the~~No. ~~existing~~333-288314) ~~symbol~~(the “~~ZJYL~~Registration Statement”), and ~~will~~to ~~begin~~be ~~trading~~a onpart aof ~~consolidation-adjusted~~the ~~basis~~Registration asStatement of from the date ~~Effective~~on ~~Date.~~which ~~The~~this ~~new~~Report ~~CUSIP~~is ~~number~~filed, ~~for~~to the ~~Class~~extent Anot ~~ordinary~~superseded ~~shares~~by ~~following~~documents ~~the~~or ~~Share~~reports ~~Consolidation~~subsequently isfiled ~~G5140V120~~or furnished.

On March 11, 2026, the Company published a press release entitled “Jin Medical International Ltd. Announces 1-for-20 Share Combination as Part of Strategic Nasdaq Compliance Initiative”, a copy of which is attached hereto as Exhibit 99.1.

This Report shall be deemed to be incorporated by reference into the registration statement on Form F-3 (File No. 333-288314), and to be a part thereof from the date on which this current report on Form 6-K is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

EXHIBIT INDEX

Exhibit No.		Description
99.1		Press Release dated ~~March~~April 117, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Jin Medical International Ltd.
Date: March 17, 2026	By:	/s/ Erqi Wang
Date: April 7, 2026	By:	/s/ Erqi Wang
		Erqi Wang
		Chief Executive Officer

Filing Compare · Jin Medical International Ltd.